Article
Cell Biology
Mo Liu, Qingwen Liu, Song Fan, Feng Su, Chun Jiang, Guanming Cai, Youyuan Wang, Guiqing Liao, Xinyuan Lei, Weixiong Chen, Junming Bi, Weiqi Cheng, LuoDan Zhao, Yi Ruan, Jinsong Li
Summary: Abnormal expression of long-noncoding RNA, LTSCCAT, is involved in the tumorigenesis and progression of tongue squamous cell carcinoma (TSCC). LTSCCAT promotes invasion and metastasis of TSCC by acting as a competitive endogenous RNA for miR-103a-2-5p to regulate metastasis-related genes.
CELL DEATH & DISEASE
(2021)
Article
Biochemistry & Molecular Biology
Lin Zhang, Wei-Ping Li
Summary: The study synthesized a novel Cu(II)-based coordination polymer to investigate the expression of miR-9-5p in cervical cancer cells. Bioinformatics analysis and luciferase reporter assay were used to confirm the interaction between miR-9-5p and BRCA1. The compound showed effects on cancer cell proliferation and ROS accumulation.
JOURNAL OF INORGANIC BIOCHEMISTRY
(2022)
Article
Oncology
Wenyan Liao, Jun He, Cyrollah Disoma, Yi Hu, Junhua Li, Guodong Chen, Ying Sheng, Xinyu Cai, Chuanfu Li, Kai Cheng, Chunfen Yang, Yongxi Qin, Dong Han, Wu Wen, Chengming Ding, Mujun Li
Summary: This study demonstrated that hsa_circ_0107593 has low expression in cervical cancer tissues and cell lines, negatively correlated with tumor characteristics, and inhibits cell proliferation, migration, and invasion. It may serve as a diagnostic biomarker due to its tumor-suppressing activity by sponging hsa-miR-20a-5p, hsa-miR-93-5p, and hsa-miR-106b-5p in cervical cancer.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Chiara Herzog, Karin Sundstrom, Allison Jones, Iona Evans, James E. Barrett, Jiangrong Wang, Elisa Redl, Lena Schreiberhuber, Laura Costas, Sonia Paytubi, Lukas Dostalek, Michal Zikan, David Cibula, Gaby Sroczynski, Uwe Siebert, Joakim Dillner, Martin Widschwendter
Summary: This study developed an automatable triage test for cervical screening that is highly sensitive and specific in predicting the risk of progression to CIN3+ in HPV+ patients. The test demonstrated a sensitivity of 100% for detecting invasive cancer and 78% for detecting CIN3, with a specificity of 90%. It also identified 52% of women aged 30 and above with a negative cytology index sample who were later diagnosed with CIN3 within 1-4 years.
CLINICAL EPIGENETICS
(2022)
Review
Oncology
Alexandros Daponte, George Michail, Athina-Ioanna Daponte, Nikoletta Daponte, George Valasoulis
Summary: Despite significant advancements in cervical cancer prevention, many women still miss the opportunity for early detection. Self-sampling HPV modalities have shown promise in addressing this issue and are considered a feasible alternative strategy with enhanced population coverage.
Article
Oncology
Garima Singh, Sonika Kumari Sharma, Samarendra Kumar Singh
Summary: MicroRNAs play an important role in regulating cell cycle and other cellular processes. This study reveals that miR-34a can suppress HPV E6 protein and destabilize Cdt2/DTL protein level in HPV-infected cervical cancer cells, leading to the suppression of cell proliferation, invasion and migration capabilities of these cells. The findings suggest the potential of miR-34a as a specific therapy for cervical cancer treatment.
Article
Oncology
Ningye Ma, Xinhui Li, Heng Wei, Huijie Zhang, Shulan Zhang
Summary: Our study revealed that circNFATC3 is upregulated in primary CC tissues and is positively correlated with tumor size and stromal invasion. Exogenous circNFATC3 overexpression enhanced the proliferation, migration, and invasion of HeLa cells, while knockdown reduced the malignancy of SiHa cells. Furthermore, circNFATC3 acts as a miR-9-5p sponge to regulate SDC2 expression and promote CC development.
Article
Biochemistry & Molecular Biology
Mingming Lu, Qing Gao, Yafei Wang, Jie Ren, Tingting Zhang
Summary: LINC00511 is up-regulated in cervical cancer and its overexpression promotes the proliferation, migration, and invasion of cervical cancer cells. LINC00511 targets miR-497-5p to up-regulate the expression of MAPK1, and this axis plays a role in the progression of cervical cancer.
Article
Oncology
Rucheng Yan, Weiwei Dai, Ruixin Wu, Houbao Huang, Minfeng Shu
Summary: Abnormal RNA methylation and dysregulation of miRNA are common in bladder cancer, and melittin has shown potential as a drug candidate for intravesical chemotherapy against bladder cancer. METTL3 has been identified as a key regulator in controlling bladder cancer cells' sensitivity to melittin-induced apoptosis, while miR-146a-5p suppression contributes to the selective antitumor effect of melittin.
Article
Medicine, Research & Experimental
Meng-Lu Chen, Chun-Gu Hong, Tao Yue, Hong-Ming Li, Ran Duan, Wen-Bao Hu, Jia Cao, Zhen-Xing Wang, Chun-Yuan Chen, Xiong-Ke Hu, Ben Wu, Hao-Ming Liu, Yi-Juan Tan, Jiang-Hua Liu, Zhong-Wei Luo, Yan Zhang, Shan-Shan Rao, Ming-Jie Luo, Hao Yin, Yi-Yi Wang, Kun Xia, Si-Yuan Tang, Hui Xie, Zheng-Zhao Liu
Summary: The study found biphasic changes of miR-331-3p and miR-9-5p in AD progression, inhibiting these two microRNAs can promote autophagic clearance of A beta and prevent AD development. This was demonstrated in experiments and offers a potential new therapeutic strategy for AD patients.
Article
Biochemistry & Molecular Biology
Delphine Garnier, Edward Ratcliffe, Josephine Briand, Pierre-Francois Cartron, Lisa Oliver, Francois M. Vallette
Summary: Glioblastoma stem cells (GSCs) can activate mesenchymal stem cells (MSCs) into cancer-associated fibroblasts (CAFs) via extracellular vesicles (EVs) and promote tumor progression through miRNA-mediated mechanisms.
Article
Oncology
Xiaomin Qin, Min Zhou, Huabing Lv, Xiaogang Mao, Xianxian Li, Hong Guo, Lin Li, Hui Xing
Summary: The study reveals that LINC00657 suppresses cervical cancer progression by inducing NK cell tolerance through regulating the miR-20a-5p/RUNX3/DR5 axis. LINC00657 acts as a tumor-suppressor by inhibiting cervical cancer cell growth and invasion.
Article
Oncology
Guolei Li, Xuhua Hu, Guiying Wang, Cuizhi Geng
Summary: This study investigated the expression and methylation levels of miR-486-5p/miR-34c-5p and its mechanism of action in colorectal cancer (CRC) using clinical data and tissue detection. The results showed low expression and high methylation levels of miR-486-5p/miR-34c-5p in circulating tumor cells (CTCs), as well as in tumor cells and tissues. Demethylation and overexpression of miR-486-5p/miR-34c-5p effectively inhibited proliferation, invasion, and migration of CRC cells, and promoted tumor apoptosis. These findings suggest that miR-486-5p/miR-34c-5p could be potential therapeutic targets for CRC.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Yan Zhang, Xing Li, Jun Zhang, Lin Mao
Summary: The expression of circ-CCDC66 was upregulated in cervical cancer and correlated with later tumor stage and larger tumor size. Circ-CCDC66 can inhibit cervical cancer cell proliferation and migration through regulating the miR-452-5p/REXO1 axis. By modulating this axis, circ-CCDC66 may serve as a potential therapeutic target for cervical cancer intervention.
CANCER CELL INTERNATIONAL
(2021)
Article
Multidisciplinary Sciences
Xuan Wang, Jun Cai, Lei Zhao, Dejun Zhang, Guojie Xu, Jianli Hu, Tao Zhang, Min Jin
Summary: Research has shown that miR-9-5p directly targets NUMB, affecting the growth and migration properties of CD44(+) PCSCs, while overexpression of NUMB can overcome the effects of miR-9-5p, providing new insights into treating PCSCs and PCa metastasis.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Angelina Huseinovic, Annelieke Jaspers, Annina P. van Splunter, Hanne Sorgard, Saskia M. Wilting, Dorian R. A. Swarts, Ida H. van der Meulen, Victor W. van Beusechem, Renee X. de Menezes, Renske D. M. Steenbergen
Summary: The progression of anchorage-dependent epithelial cells to anchorage-independent growth is a critical feature of malignant transformation. In this study, the researchers used an in vitro model of HPV-induced transformation to investigate the role of microRNAs in anchorage-independent growth. They developed alternative functional screening methods using ultra-low attachment plates and identified a set of microRNAs that consistently suppressed growth. These microRNAs may serve as specific biomarkers for detecting and treating HPV-induced precancerous lesions progressing to invasive cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Y. M. Meyer, S. M. Wilting, J. Kraan, P. Olthof, P. Vermeulen, J. Martens, D. J. Grunhagen, S. Sleijfer, C. Verhoef
Summary: This study examined the association between preoperative measurement of Circulating Tumour Cells (CTCs) and Histopathological Growth Patterns (HGPs) in patients with Colorectal Liver Metastases (CRLM). The results showed that the preoperative absence of CTCs was associated with desmoplastic HGP (dHGP) in chemo naive CRLM patients without extrahepatic disease. The integration of CTC count in multivariable prediction models may aid in the preoperative identification of HGPs of CRLM.
CLINICAL & EXPERIMENTAL METASTASIS
(2022)
Review
Oncology
Jan M. Van Rees, Lissa Wullaert, Alexander A. J. Grueter, Yassmina Derraze, Pieter J. Tanis, Henk M. W. Verheul, John W. M. Martens, Saskia M. Wilting, Geraldine Vink, Jeroen L. A. Van Vugt, Nick Beije, Cornelis Verhoef
Summary: This systematic review and meta-analyses demonstrate a strong association between ctDNA and recurrent disease in non-metastatic rectal cancer. ctDNA analysis can stratify patients into high and low risk groups for recurrence, especially when detected after neoadjuvant treatment and surgery. Future research should focus on the feasibility of ctDNA-guided treatment and follow-up strategies in rectal cancer.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Khrystany T. Isebia, Bianca Mostert, Teoman Deger, Jaco Kraan, Vanja de Weerd, Esther Oomen-de Hoop, Paul Hamberg, Brigitte C. M. Haberkorn, Helgi H. Helgason, Ronald de Wit, Ron H. J. Mathijssen, Martijn P. Lolkema, Saskia M. Wilting, Job van Riet, John W. M. Martens
Summary: In this study, the researchers found that the abnormal aneuploidy score of cell-free tumor DNA (ctDNA) in the blood can predict the survival of metastatic castration-resistant prostate cancer (mCRPC) patients, making it a potential biomarker.
MOLECULAR ONCOLOGY
(2023)
Article
Oncology
Manouk K. Bos, Sarah R. Verhoeff, Sjoukje F. Oosting, Willemien C. van der Houven van Oordt, Ruben G. Boers, Joachim B. Boers, Joost Gribnau, John W. M. Martens, Stefan Sleijfer, Carla M. L. van Herpen, Saskia M. Wilting
Summary: For patients with intermediate risk renal cell carcinoma, some have a slow disease progression. Delaying treatment for metastatic disease by entering a watchful waiting period is a safe option for these patients. However, it is currently difficult to identify patients with indolent disease or those with rapidly progressive disease. This study investigates the use of cell-free DNA (cfDNA) as a blood-based biomarker to identify patients with rapid disease progression.
Article
Oncology
Elisabeth M. Jongbloed, Hedwig M. Blommestein, Hannah M. van Schoubroeck, John W. M. Martens, Saskia M. Wilting, Carin A. Uyl-de Groot, Agnes Jager
Summary: The addition of two years of abemaciclib treatment to high-risk ER+, HER2-early breast cancer patients has been approved by the FDA. Using detection of minimal residual disease (MRD) through patient-informed circulating tumor DNA assays, the addition of abemaciclib treatment shows cost-effectiveness for high-risk patients. However, adding abemaciclib to all high-risk patients is not cost-effective, while MRD-guided treatment is more cost-effective compared to standard treatment.
BREAST CANCER-TARGETS AND THERAPY
(2023)
Article
Immunology
Iris A. E. van der Hoorn, Evgenia Martynova, Beatriz Subtil, Jelena Meek, Kiek Verrijp, Johannes Textor, Georgina Florez-Grau, Berber Piet, Michel M. van den Heuvel, I. Jolanda M. de Vries, Mark A. J. Gorris
Summary: This paper describes the development, validation, and quantitative analysis of a multiplex immunohistochemistry panel pipeline with which conventional type 1 dendritic cells (cDC1s), cDC2s, and plasmacytoid DCs can be detected in the spatial context of the tumor microenvironment.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Elisabeth M. Jongbloed, Maurice P. H. M. Jansen, Vanja de Weerd, Jean A. Helmijr, Corine M. Beaufort, Marcel J. T. Reinders, Ronald van Marion, Wilfred F. J. van IJcken, Gabe S. Sonke, Inge R. Konings, Agnes Jager, John W. M. Martens, Saskia M. Wilting, Stavros Makrodimitris
Summary: Next generation sequencing of cfDNA is a promising method for treatment monitoring and therapy selection in MBC. However, distinguishing tumor-specific variants from sequencing artefacts and germline variation is challenging. To address this, a machine learning model was built to remove false positive variant calls and select tumor-derived variants.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Siyu Fu, Teoman Deger, Ruben G. Boers, Joachim B. Boers, Michael Doukas, Joost Gribnau, Saskia M. Wilting, Jose D. Debes, Andre Boonstra
Summary: In this study, aberrant hypermethylation changes in HOXA1, CLEC11A, AK055957, and TSPYL5 were identified in non-cirrhotic HCC tissues compared to cirrhosis, hepatitis, and benign lesions, providing potential detectable biomarkers for these unusual HCC cases.
Article
Oncology
Ellis L. Eikenboom, Saskia M. Wilting, Teoman Deger, Malgorzata I. Srebniak, Monique Van Veghel-Plandsoen, Ruben G. Boers, Joachim B. Boers, Wilfred F. J. van IJcken, Joost H. Gribnau, Peggy Atmodimedjo, Hendrikus J. Dubbink, John W. M. Martens, Manon C. W. Spaander, Anja Wagner
Summary: We assessed which ctDNA assay might be most suitable for a ctDNA-based CRC screening/surveillance blood test. The results showed that cfDNA methylation profiles could discriminate all microsatellite instable advanced neoplasia, making it a particularly promising tool for Lynch syndrome surveillance. Larger studies are needed to validate these findings.
Article
Oncology
Lindsay Angus, Marcel Smid, Saskia M. Wilting, Manouk K. Bos, Neeltje Steeghs, Inge R. H. M. Konings, Vivianne C. G. Tjan-Heijnen, Johanna M. G. H. van Riel, Agnes J. van de Wouw, Edwin Cuppen, Martijn P. Lolkema, Agnes Jager, Stefan Sleijfer, John W. M. Martens
Summary: This study investigated the mutated genes and mutation patterns, as well as the expression levels of relevant genes, in 101 breast cancer metastatic lesions with ER-positive tumors. The analyses revealed two distinct patient groups, one showing ongoing, active ER and its associated signal route, and the other showing lower ER expression levels. The study highlights the importance of combining mutation and expression analyses to identify patients who may still benefit from anti-hormonal treatment targeting ER.
Review
Cell Biology
Lissa Wullaert, Jan M. van Rees, John W. M. Martens, Henk M. W. Verheul, Dirk J. Grunhagen, Saskia M. Wilting, Cornelis Verhoef
Summary: This study provides an overview and meta-analysis of the current literature on the value of ctDNA in patients with colorectal liver metastases. The results show a strong association between detectable ctDNA after surgery or completion of adjuvant therapy and oncological outcomes. However, there is no association between detectable ctDNA before surgery and oncological outcomes.
Article
Oncology
Noortje Verschoor, Vanja de Weerd, Mai N. Van, Jaco Kraan, Marcel Smid, Joan B. Heijns, Jan C. Drooger, Johanna M. Zuetenhorst, Annemieke van der Padt-pruijsten, Agnes Jager, Stefan Sleijfer, John W. M. Martens, Saskia M. Wilting
Summary: This study demonstrates that mFAST-SeqS can serve as a strong prognostic marker for MBC patients. It is an affordable and easily implementable method for assessing ctDNA levels, offering an alternative tool for prognosis. The aneuploidy score obtained using mFAST-SeqS is significantly correlated with CTC count and is a significant prognostic marker for both PFS and OS in MBC patients.
Article
Oncology
D. M. Mens, J. M. van Rees, S. M. Wilting, C. Verhoef
Summary: Chemoradiation therapy (CRT) is the standard of care for treating rectal cancer, but it can cause damage to the surrounding healthy tissue and not all patients benefit from it. This study aims to develop a diagnostic innovation using DNA methylation to predict the effectiveness of CRT for rectal cancer patients.
Article
Oncology
Noortje Verschoor, Marcel Smid, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting, John W. M. Martens
Summary: In this study, the researchers investigated the characteristics and therapy resistance of HER2-positive breast cancer through integrating genomics and transcriptomics data. They found that the genomic profiles of primary and metastatic HER2-positive breast cancers were similar, and certain genomic features were predictive of progression-free survival on post-biopsy anti-HER2 treatment. Additionally, a HER2-driven expression profile grouped different types of HER2-positive tumors and indicated the possibility of transformation to ER independence. Integrated genomic and transcriptomic analyses may play a key role in establishing therapeutic options.
BREAST CANCER RESEARCH
(2023)